Loading...
XNAS
ATRC
Market cap1.75bUSD
Jul 09, Last price  
34.56USD
1D
2.67%
1Q
22.42%
Jan 2017
76.60%
IPO
143.38%
Name

AtriCure Inc

Chart & Performance

D1W1MN
XNAS:ATRC chart
P/E
P/S
3.27
EPS
Div Yield, %
Shrs. gr., 5y
2.54%
Rev. gr., 5y
20.95%
Revenues
535m
+14.88%
38,243,24348,309,06355,257,02354,533,55859,006,18864,402,40970,247,00081,889,000107,454,000129,755,000155,109,000174,716,000201,630,000230,807,000206,531,000274,329,000330,379,000399,245,000465,307,000534,528,000
Net income
-11m
L-74.39%
-13,717,275-11,253,066-10,167,252-16,494,988-3,791,623-5,455,503-7,534,000-11,462,000-16,211,000-27,212,000-33,338,000-26,892,000-21,137,000-35,194,000-48,155,00050,199,000-46,466,000-30,438,000-44,698,000-11,448,000
CFO
57m
+369.80%
-12,465,730-8,115,628-5,709,940419,948-33,434-1,986,426-1,936,000-5,222,000-21,600,000-7,842,000-15,119,000-8,944,000-4,171,000-15,811,000-19,869,000-13,780,000-22,141,0004,484,00012,204,00057,334,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
IPO date
Aug 05, 2005
Employees
1,050
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT